Reporting quality of polycystic ovary syndrome practice guidelines based on the RIGHT checklist

Abstract

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder involving hyperandrogenism, menstrual disorder, metabolic problems, infertility, obesity, and acne. The main aim of this study was to assess the reporting quality of clinical practice guidelines (CPGs) in the field of PCOS to provide a reporting specification for this study. Methods: We evaluated the reporting quality of clinical guidelines of PCOS using the Reporting Items for Practice Guidelines in HealThcare (RIGHT) checklist. Nine databases and 3 medical associations were searched. These included Medline, Embase, PubMed, National Institute for Health and Care Excellence (NICE), Guidelines International Network (GIN), National Guideline Clearinghouse (NGC), China National Knowledge Infrastructure, Wanfang and Chinese Science, and Technology Journal Database (VIP). Three medical associations included the European Society of Human Reproduction and Embryology, the American Society for Reproductive Medicine and the Agency for Healthcare Research and Quality. Two independent authors assessed the reporting quality of PCOS CPGs by the RIGHT checklist, and Spearman's correlation was used to assess inter-rater reliability. Results: Twelve PCOS CPGs were included. On average, 20.0 (57.1%) of the 35 items in the RIGHT checklist were reported. All items were fully reported by one of these CPGs. The number of reported items ranged from 10 (28.6%) to 35 (100%). Overall, 16.7%, 66.7%, and 16.7% of included guidelines were of high, medium, and low quality, respectively. The reporting proportions of the 7 domains (i.e., Basic information, Background, Evidence, Recommendations, Reviewand quality assurance, Funding and declaration and management of interests, and Other information) in the RIGHT checklist were 62.0%, 69.1%, 53.3%, 60.7%, 33.3%, 31.2%, and 69.4%, respectively. Conclusions: The evaluation of these CPGs by the RIGHT checklist revealed that the reporting quality varied among guidelines. Low quality items were the processes of evidence decision and the declaration of funding in most included CPGs. Guideline developers should pay more attention to these items to disseminate and implement better guidelines in near future. Trial registration number: registration at PROSPERO CRD42020163435

Quality Evaluation of Clinical Practice Guidelines and the Recommendations for Esophageal Cancer

“…"Funding and declaration and management of interests" is a low reporting quality domain with a 35.00% average reporting proportion. This result in line with other studies [25,27] . No guideline describes the role of funding in the dissemination and implementation of recommendations later(18b,0%), or even make no mention of funding information(18a,53.33%).…”

Research Progress on the Relationship Between Mitochondrial Dysfunction and Premature Ovarian Failure from the Perspective of TCM Treatment

“…According to a study [15] , the effects of oxidative stress on ovarian function are as follows: (1) oxidative stress damages cells and leads to oocyte apoptosis; granulosa cells are sensitive to oxidative stress damage, and oocytes, in the active state of meiosis, are more susceptible to oxidative stress damage; (2) oxidative stress leads to the destruction of mitochondrial structure, resulting in the destruction of mitochondrial DNA;…”

Suplementação Do Ômega-3 E Da Vitamina D Na Atenuação Dos Sintomas Da Síndrome Dos Ovários Policísticos

“…A Anovulação Crônica Hiperandrogênica é considerada uma endocrinopatia complexa intitulada de Síndrome do Ovário Policístico (SOP), sendo caracterizada como um transtorno multigênico, podendo ter sua origem a partir do ambiente intrauterino devido a exposição por andrógenos e/ou influências externas, incluindo os hábitos alimentares 1,2 . Diante disso, segundo os dados epidemiológicos mundiais, a SOP atinge frequentemente mulheres de 18 a 44 anos com uma incidência de 6 a 15%, onde suas manifestações se iniciam principalmente na adolescência, e, até 70% das mulheres não tem diagnóstico 3 .…”